DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
If you suffered losses exceeding $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and would like to ...
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
Regeneron Pharmaceuticals Inc. closed 42.77% short of its 52-week high of $1,211.20, which the company achieved on August ...
Hosted on MSN19h
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...
Is Amgen Inc. (AMGN) Among the Best NASDAQ Dividend Stocks to Buy?
We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...
UBS cuts rating on Regeneron stock amid Eylea uncertainty
UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $2,688.18 today based on a ...
Regeneron Pharmaceuticals, Inc. Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the REGN Class Action
SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...
BioAge Labs, Inc. Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the BIOA Class Action
SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...
Gilead reportedly settles CDC patent dispute over HIV drugs
Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of ...
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’
We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...